The failure to achieve statistical significance in the primary endpoint of overall survival in the Phase 3 trial is a significant setback for G1 Therapeutics. This outcome likely diminishes investor confidence in the company's future prospects and the potential marketability of Trilaciclib, leading to a short-term negative impact on the stock price.